Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 24, 2025 (1 years ago)

Rapidol Maximum Strength (Hydrocortisone)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Rapidol Maximum Strength, Hydrocortisone 1% Anti-Itch Cream, NET WT 2 oz (60g) Tube, Distributed by: Pharmadel LLC, New Castle, DE, 19720, NDC 55758-420-02, UPC 8 10096 77158 2.

Affected NDC 55758-0420-02

Compare with the code on your package — it is the most precise check available.

Drug: Hydrocortisone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Rapidol
Hydrocortisone
NDC 55758-0420
1 g/100g Cream
Topical
Pharmadel LLC OTC
Recalling firm
Kenil Healthcare Private Limited
NDC code
55758-420-02
Origin
N/A, India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0428-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrocortisone recalls

See all
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0640-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0639-2026
Class III · Low risk

Skin Rehab

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk

Remedy Gel

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026

Other recalls by Kenil Healthcare Private Limited

All 2025 recalls
Class II · Moderate risk

Nature Mint

CGMP Deviations

Terminated cGMP deviation Kenil Healthcare Private Limited NDC 53247-131-05 D-0440-2025
Class II · Moderate risk

Nature Mint

CGMP Deviations

Terminated cGMP deviation Kenil Healthcare Private Limited NDC 53247-131-07 D-0437-2025